search
Back to results

Expanded Access to VAL-083

Primary Purpose

Cancer

Status
Available
Phase
Locations
Study Type
Expanded Access
Intervention
VAL-083
Sponsored by
Kintara Therapeutics, Inc.
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an expanded access trial for Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All Sexes

Inclusion Criteria:

  • Patient has relapsed/refractory disease and exhausted all standard treatments.

Exclusion Criteria:

  • Patient is eligible for a VAL-083 clinical trial.
  • Patient has previously received VAL-083 for the same disease.

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Secondary Outcome Measures

    Full Information

    First Posted
    May 1, 2017
    Last Updated
    November 14, 2021
    Sponsor
    Kintara Therapeutics, Inc.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03138629
    Brief Title
    Expanded Access to VAL-083
    Official Title
    Expanded Access to VAL-083
    Study Type
    Expanded Access

    2. Study Status

    Record Verification Date
    November 2021
    Overall Recruitment Status
    Available
    Study Start Date
    undefined (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Kintara Therapeutics, Inc.

    4. Oversight

    5. Study Description

    Brief Summary
    This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to VAL-083 (dianhydrogalactitol) prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Cancer

    7. Study Design

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    VAL-083
    Intervention Description
    VAL-083 will be administered intravenously

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Eligibility Criteria
    Inclusion Criteria: Patient has relapsed/refractory disease and exhausted all standard treatments. Exclusion Criteria: Patient is eligible for a VAL-083 clinical trial. Patient has previously received VAL-083 for the same disease.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    John Langlands, Ph.D
    Phone
    (604) 629-5989
    Email
    jlanglands@kintara.com

    12. IPD Sharing Statement

    Learn more about this trial

    Expanded Access to VAL-083

    We'll reach out to this number within 24 hrs